Eischer L, Gartner V, Schulman S, Kyrle PA, Eichinger S; investigators A-F. 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII. Ann Hematol. 2009;88(5):485-490. 228. Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med. 2007;147(11):766-774. 229. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. The Cochrane Database System Rev. 2014;1: CD002783. 230. Enden T, Wik HS, Kvam AK, Haig Y, Klow NE, Sandset PM. Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open. 2013;3(8): e002984. 231. Douketis JD, Foster GA, Crowther MA, Prins MH, Ginsberg JS. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med. 2000;160(22):3431-3436. 232. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008;149(10):698-707. 233. Piazza G, Goldhaber SZ. Fibrinolysis for acute pulmonary embolism. Vasc Med. 2010;15(5):419-428. 234. Mehta RH, Stebbins A, Lopes RD, et al. Race, bleeding, and outcomes in STEMI patients treated with brinolytic therapy. Am J Med. 2011;124(1):48-57. 235. Todd JL, Tapson VF. Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. Chest. 2009;135(5):1321-1329. 236. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke. 2000;31(8):1802-1811. 237. Mismetti P, Laporte S, Pellerin O, et al; and the PREPIC 2 Study Group. Effect of a retrievable inferior vena cava lter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. 